Phospholipase C-β3 Regulates FcɛRI-Mediated Mast Cell Activation by Recruiting the Protein Phosphatase SHP-1  by Xiao, Wenbin et al.
Immunity
ArticlePhospholipase C-b3 Regulates Fc3RI-Mediated
Mast Cell Activation by Recruiting
the Protein Phosphatase SHP-1
Wenbin Xiao,1,4 Jun-ichi Kashiwakura,1 Hong Hong,1,5 Hiroki Yasudo,1 Tomoaki Ando,1 Mari Maeda-Yamamoto,2
Dianqing Wu,3 Yuko Kawakami,1 and Toshiaki Kawakami1,*
1Division of Cell Biology, La Jolla Institute for Allergy and Immunology, La Jolla, CA 92037, USA
2National Institute of Vegetables and Tea Science, National Agriculture Research Organization, Shizuoka 428-8501, Japan
3Program for Vascular Biology and Therapeutics and Department of Pharmacology, Yale University School of Medicine, New Haven,
CT 06520, USA
4Present address: Department of Pathology, University Hospitals Case Medical Center, Case Western Reserve University, Cleveland,
OH 44106, USA
5Present address: Case Cardiovascular Research Institute, Department of Medicine, Case Western Reserve University, Cleveland,
OH 44106, USA
*Correspondence: toshi@liai.org
DOI 10.1016/j.immuni.2011.04.010SUMMARY
Mast cells are major effectors in high-affinity IgE
receptor (Fc3RI)-dependent allergic reactions. Here
we show that phospholipase C (PLC)-b3 is crucial
for Fc3RI-mediated mast cell activation. Plcb3/
mice showed blunted Fc3RI-dependent late-phase,
but not acute, anaphylactic responses and airway
inflammation. Accordingly, Fc3RI stimulation of
Plcb3/ mast cells exhibited reduced cytokine pro-
duction but normal degranulation. Reduced cytokine
production in Plcb3/ cells could be accounted for
by increased activity of the negative regulatory Src
family kinase Lyn and reduced activities of the posi-
tive regulatory protein kinases MAPKs. Mechanisti-
cally, PLC-b3 constitutively interacts with Fc3RI,
Lyn, and SHP-1 (protein phosphatase). SHP-1 prob-
ably recognizes its substrates Lyn and MAPKs via
the recently described kinase tyrosine-based inhibi-
tory motif, KTIM. Consistent with PLC-b3- and
SHP-1-mediated repression of Lyn activity by
dephosphorylation at Tyr396, Fc3RI-mediated
phenotypes were similar in Plcb3/ and SHP-1
mutant mast cells. Thus, we have defined a PLC-
b3- and SHP-1-mediated signaling pathway for
Fc3RI-mediated cytokine production.
INTRODUCTION
Mast cells are key effector cells for IgE-dependent allergic
inflammatory reactions (Galli et al., 2005). Upon activation,
mast cells secrete preformed proinflammatory chemical media-
tors (e.g., histamine), proteases, proteoglycans, and nucleo-
tides, as well as de novo synthesized lipids (e.g., leukotrienes
and prostaglandins) and polypeptides (e.g., cytokines). These
substances lead to the development of allergic inflammation.Fc3RI, the high-affinity IgE receptor expressed on themast cell
surface, is a tetrameric complex consisting of an IgE-binding
a subunit, a signal-modulating b subunit, and two copies of the
signal-generating g subunit (Kinet, 1999). Aggregation of
IgE-bound Fc3RI induced by specific multivalent antigen (Ag)
results in activation of b chain-associated Lyn, a Src family
kinase (SFK). Lyn phosphorylates tyrosine residues within the
immunoreceptor tyrosine-based activation motifs (ITAMs) in
the cytoplasmic domains of the b and g chains, which leads to
the recruitment of additional Lyn to the b chain, another protein
tyrosine kinase (PTK), Syk, to the g chains, and other signaling
and scaffolding molecules to the aggregated receptor complex
(Gilfillan and Rivera, 2009; Gilfillan and Tkaczyk, 2006; Rivera
and Gilfillan, 2006; Turner and Kinet, 1999). Another SFK, Fyn,
is also known to associate with Fc3RI and to play a complemen-
tary role by activating phosphatidylinositol 3-kinase (PI3K)
(Parravicini et al., 2002). These PTKs phosphorylate numerous
targets and activate several signaling pathways, leading to
mast cell activation (Kalesnikoff and Galli, 2008).
Activation signals are strictly counterbalanced by negative
signalingmolecules, such as Src homology 2 (SH2) domain-con-
taining inositol 50-phosphatases, SHIP-1 and -2, and SH2
domain-containing protein phosphatase-1 (SHP-1). Tyrosine-
phosphorylated SHIP-1 binds Fc3RIb chain via a phosphorylated
ITAM (Kimura et al., 1997a). SHIP-1-deficient mast cells show
increased degranulation after IgE stimulation, which is correlated
with a higher and more sustained intracellular calcium concen-
tration (Gimborn et al., 2005; Huber et al., 1998). SHIP-1 also
negatively regulates cytokine production through multiple path-
ways: in SHIP-1-deficient cells, PI3K, Akt, and protein kinase C
(PKC) elevate interleukin-6 (IL-6) mRNA synthesis by enhancing
the phosphorylation of the inhibitor of kBa (IkBa) and increasing
NF-kB DNA binding while ERK and p38 pathways enhance IL-6
mRNA synthesis by increasing the transactivation potential of
NF-kB (Kalesnikoff et al., 2002). SHIP-1 is largely phosphory-
lated by Lyn (Hernandez-Hansen et al., 2004; Hibbs et al.,
2002; Xiao et al., 2005). Thus, Lyn negatively regulates mast
cell activation in vivo and in vitro (Hernandez-Hansen et al.,
2004; Kawakami et al., 2000; Odom et al., 2004), although itsImmunity 34, 893–904, June 24, 2011 ª2011 Elsevier Inc. 893
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(Poderycki et al., 2010; Tolar et al., 2004; Xiao et al., 2005).
SHIP-2 is also known to inhibit degranulation and cytokine
production (Leung and Bolland, 2007). On the other hand,
SHP-1 is generally considered a negative regulator of mast cell
activation (Ott and Cambier, 2000). However, the data on SHP-
1 in mast cell activation have been inconsistent. Overexpression
of SHP-1 in a rat mast cell line, RBL-2H3, results in increased
cytokine production upon IgE+Ag stimulation (Xie et al., 2000).
By contrast, mast cells derived from SHP-1 loss-of-expression
mutant motheaten (me/me) mice show increased cytokine
production, but reduced calcium mobilization and degranula-
tion, implying that SHP-1 has both negative and positive roles
(Nakata et al., 2008).
PLC is a family of enzymes that catalyze the hydrolysis of
phosphatidylinositol 4,5-bisphosphate to generate diacylgly-
cerol and inositol 1,4,5-trisphosphate, leading to the activation
of PKC and the mobilization of intracellular Ca2+. Molecular
cloning has identified 13mammalian PLC isozymes that are clas-
sified into six subfamilies (PLC-b, PLC-g, PLC-d, PLC-3, PLC-z,
and PLC-h) (Suh et al., 2008). Different PLC isozymes appear to
be activated by different receptors and mechanisms, for
example, PLC-b by G protein-coupled receptors (GPCRs) and
PLC-g by PTK-based receptors (Rhee, 2001). In mast cells,
PLC-g2 is absolutely required for Fc3RI-mediated calciummobi-
lization, degranulation, and cytokine production, which cannot
be compensated by the concurrently expressed PLC-g1
(Wang et al., 2000). The function of other PLC members in
mast cells is largely unknown. Recently, we have reported that
PLC-b3 can form the multimolecular SPS complex containing
SHP-1, PLC-b3, and Stat5 and facilitate the catalytic activity
of SHP-1 in hematopoietic stem cells (Xiao et al., 2009). Because
SHP-1 has been shown to regulate Fc3RI-mediated mast cell
activation, we set out to study the function of PLC-b3 in mast
cells.
RESULTS
PLC-b3 Is Required for In Vivo Mast Cell Functions
To investigate the role of PLC-b3 in in vivomast cell functions, we
induced two types of mast cell-dependent immune responses,
i.e., passive cutaneous anaphylaxis (PCA) and airway inflamma-
tion, in mice. The Fc3RI-dependent PCA response is promoted
by histamine and serotonin released from activated mast cells
in the acute phase (Inagaki et al., 1986) and in part by mast
cell-derived tumor necrosis factor-a (TNF-a) in the late phase
(Wershil et al., 1991). We confirmed that mast cell numbers in
ear skin were comparable in 6-week-old wild-type (WT) and
Plcb3/mice (15.92 ± 1.45 versus 18.25 ± 0.55 per high-power
field; p = 0.18, n = 4 each). In PCA experiments, both WT and
Plcb3/ mice exhibited an increased vascular permeability
(Figure 1A) and edema (Figure 1B) as early as 30 min after Ag
challenge and there was no difference between these two geno-
types, indicating that mast cell-mediated acute-phase PCA
reactions do not require PLC-b3. Within 2 hr after Ag challenge,
the ear thickness representing edema was reduced in Plcb3/
mice to that similar to non-Ag-challenged control. However,
ears in WT mice were still edematous, significantly more than
those of Plcb3/ mice until 6 hr later (Figure 1B; see Figure S1894 Immunity 34, 893–904, June 24, 2011 ª2011 Elsevier Inc.available online), demonstrating that PLC-b3 is required for full
late-phase reactions. To investigate the PLC-b3 function in
mast cells more directly, mast cell-deficient KitW-sh/W-sh mice
were engrafted with bone marrow-derived mast cells (BMMCs)
fromWTorPlcb3/mice (see Figures 2A and 2B) and subjected
to PCA experiments. Comparable numbers of the engrafted
mast cells were confirmed by toluidine blue staining (WT
8.37 ± 1.06 per high-power field versus Plcb3/ 8.68 ± 1.47).
Results showed a reduced late-phase response in Plcb3/
cell-engrafted mice compared to WT cell-engrafted mice (Fig-
ure 1C), indicating that PLC-b3 is essential for in vivo mast cell
functions.
Mast cell-dependent chronic airway inflammation was
induced in mice according to the published protocol of oval-
bumin (OVA) sensitization (without adjuvant) followed by intra-
nasal OVA challenges (Williams and Galli, 2000). Inflammation
characterized by the accumulation of eosinophils and goblet
cell hyperplasia, hallmarks of airway inflammation, was seen.
Consistent with type 2 inflammation, IL-5 and IL-13 in the lung
homogenates were increased. However, these features were
drastically reduced in Plcb3/ mice, although Plcb3/ mice
had increased macrophages in lungs at baseline (Figures 1D–
1F). A similar OVA sensitization and OVA challenge model shows
the important role of Fc3RI in airway inflammation (Taube et al.,
2004). Thus, both PCA and airway inflammation data strongly
suggest the important role of PLC-b3 in Fc3RI-mediated in vivo
mast cell activation, particularly in the late and chronic phases
of allergic inflammation.
PLC-b3 Regulates Fc3RI-Mediated Migration and
Cytokine Production, but Not Degranulation
To study how PLC-b3 regulates the function of mast cells, we
cultured bone marrow cells derived from WT and Plcb3/
mice in the presence of IL-3. Four weeks later, more than 90%
pure populations of mast cells were generated from both types
of cells, as determined by surface staining of c-Kit (receptor tyro-
sine kinase for stem cell factor [SCF]) and Fc3RI (Figure 2A).
Microscopic analysis of May-Gru¨nwald-stained mast cells re-
vealed an indistinguishable metachromatic cell morphology
(Figure 2B). These results suggest that PLC-b3 is not required
for mast cell development.
Consistent with the similar acute-phase PCA reactions (Fig-
ure 1A), Ag stimulation of IgE-sensitized cells (IgE+Ag) induced
similarly potent histamine release in WT and Plcb3/ cells (Fig-
ure 2C). Moreover, IgE+Ag-induced Ca2+ mobilization, which is
required for mast cell degranulation (Ozawa et al., 1993), was
not different between WT and Plcb3/ cells (Figure 2D).
Migration and cytokine production are cardinal features of
Fc3RI-induced mast cell activation (Galli et al., 2005). Therefore,
we compared these responses between WT and Plcb3/ cells.
IgE-sensitized WT cells were attracted toward Ag, whereas this
chemotactic response was drastically decreased in Plcb3/
cells (Figure 3A). PLC-b3 functions downstream of GPCRs
(Rhee, 2001). Therefore, we also examined chemotaxis induced
by GPCR ligands, including RANTES (CCL5), MIP-1a (CCL3),
and adenosine. Although, compared to antigen, all of these
stimuli induced stronger migration of mast cells, there was no
significant difference between WT and Plcb3/ cells (Figure 3B
and data not shown). Furthermore, SCF-induced chemotaxis
Figure 1. Reduced Late-Phase PCA Response and Mast Cell-Dependent Airway Inflammation in Plcb3–/– Mice
(A–C) PCA reactions were induced as described in the Experimental Procedures.
(A) Vascular permeability was measured by quantifying Evans blue dye that leaked into ears 30 min after antigen challenge. WT, n = 4; Plcb3/, n = 7.
(B and C) Ear thicknesses during PCA responses were measured in WT and Plcb3/ mice.
(C) KitW-sh/W-sh mice were engrafted at their ears with BMMCs derived fromWT or Plcb3/mice 6–8 weeks before PCA experiments. Results are expressed as
mean ± SEM. *p < 0.05 versus WT mice. n = 5 each.
(D–F) Mast cell-dependent airway inflammation was induced as described in the Experimental Procedures.
(D) Total and differential cell counts in BALF. *p < 0.05; **p < 0.01; ***p < 0.001. Error bars represent SEM; n = 6 per group. Eos, eosinophils; Neu, neutrophils; Lym,
lymphocytes; Mf, macrophages or monocytes.
(E) IL-5 and IL-13 amounts in lung homogenates were measured by ELISA. n = 6 per group.
(F) Lung tissue sections were stained with H&E and PAS. Scale bars represent 200 mm. Data are representative of two independent experiments.
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these results indicate that PLC-b3 selectively and positively
regulates Fc3RI-mediated mast cell migration.
Next, we measured cytokine production by mast cells stimu-
lated by IgE+Ag. Similar to the positive role of PLC-b3 in migra-
tion, production of IL-6, TNF-a, and IL-13 from Plcb3/ cells
was substantially reduced, compared to WT cells (Figures 3C–
3E). These results can explain the reduced late-phase PCA reac-tion in Plcb3/mice, because TNF-awas reported as one of the
major mediators responsible for IgE-dependent late-phase PCA
reactions (Wershil et al., 1991).
Increased Lyn Kinase Activity in Plcb3–/– Mast Cells
To investigate how PLC-b3 positively regulates Fc3RI-induced
cytokine production and chemotaxis, we compared the profiles
of tyrosine phosphorylation in WT and Plcb3/ cells. HigherImmunity 34, 893–904, June 24, 2011 ª2011 Elsevier Inc. 895
Figure 2. Plcb3–/– BMMCs Display WT Phenotypes of Degranulation and Calcium Mobilization
Bone marrow cells were harvested from WT and Plcb3/ mice and grown in media containing IL-3 for 4–6 weeks.
(A) Surface expression of Fc3RI and c-Kit on 4-week-old BMMCs derived from WT and Plcb3/ mice was assayed by flow cytometry.
(B) May-Gru¨nwald-stained BMMCs. Scale bar represents 20 mm.
(C) BMMCs were sensitized overnight with anti-DNP IgE, washed, and then stimulated with the indicated concentrations of DNP23-HSA (Ag) for 45 min for
histamine release. n = 4 each. Error bars represent SD.
(D) Ca2+ flux was measured with BMMCs loaded with Indo 1-AM and stimulated with the indicated concentrations of Ag (indicated by arrow), followed by the
addition of 1 mg/ml ionomycin (indicated by double arrow). n = 4 each. Results shown are representative of at least three independent experiments.
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including those of 53 kD and 56 kD in Plcb3/ cells, before
and after IgE+Ag stimulation (Figure 4A). Consistent with this,
phosphorylation amounts of Tyr396 of p53lyn and p56lyn were
dramatically increased in Plcb3/ cells, whereas phosphoryla-
tion of Lyn-Tyr507 was only slightly increased (Figure 4B). These
results indicate an increased Lyn kinase activity inPlcb3/ cells,
because Lyn activity like other SFKs is regulated positively by
phosphorylation at the activation-loop tyrosine residue and
negatively by phosphorylation at the C-terminal tyrosine residue
(Hunter, 1995). By contrast, tyrosine phosphorylation of Fyn was
not different between WT and Plcb3/ cells (data not shown).896 Immunity 34, 893–904, June 24, 2011 ª2011 Elsevier Inc.Therefore, PLC-b3 selectively and negatively regulates Lyn
kinase activity.
Consistent with the increased Lyn-Tyr396 phosphorylation in
Plcb3/ cells, tyrosine phosphorylation of downstream targets
of Lyn, such as Fc3RI b subunit and Syk, was increased before
stimulation (Figure 4C). Previous studies demonstrate that tyro-
sine phosphorylation of SHIP-1, an important negative regulator
in mast cells, was dependent on Lyn and Fc3RI b ITAM (Furu-
moto et al., 2004; Hernandez-Hansen et al., 2004; Xiao et al.,
2005). Consistent with the increased Lyn-Tyr396 and Fc3RI
b phosphorylation, tyrosine phosphorylation of SHIP-1 was up-
regulated in Plcb3/ cells compared to WT cells (Figure 4D).
Figure 3. Plcb3–/– BMMCs Exhibit Reduced
Migration and Cytokine Production
(A and B) BMMCs were sensitized overnight with
anti-DNP IgE, and then migration assays were
performed in transwell chambers with the indi-
cated concentrations of DNP23-HSA (Ag), adeno-
sine (Ad), or SCF as chemoattractants. n = 5 each.
Results shown are representative of three inde-
pendent experiments.
(C–E) Cytokines from IgE+Ag-stimulated BMMCs
were quantified by ELISA. n = 8 each. Error bars
represent SD. Representative of three indepen-
dent experiments.
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Phospholipase C-b3 in Mast Cell ActivationActivation of Fc3RI leads to tyrosine phosphorylation of linker
of activated T cells (LAT), Bruton’s tyrosine kinase (Btk), and
PLC-g2, thus triggering calcium mobilization, a crucial step for
degranulation (Fluckiger et al., 1998; Saitoh et al., 2000; Wang
et al., 2000). Although the proximal signaling events such as acti-
vation of Lyn and Syk were enhanced in Plcb3/ cells, phos-
phorylation of LAT, Btk, and PLC-g2 was not different from
that in WT cells (Figure 5A), consistent with the comparable
calciummobilization betweenWT and Plcb3/ cells (Figure 2D).
Activities of MAPKs Are Positively Regulated by PLC-b3
MAPKs are important positive regulators for Fc3RI-induced mast
cell activation. Therefore, we compared activities of these
signaling molecules between WT and Plcb3/ cells. Stimulation
with IgE+Ag induced robust phosphorylation and thus activation
of MAPKs (p38, JNK1, JNK2, ERK1, and ERK2) in WT cells (Fig-
ure 5B). By contrast, there was drastically reduced activation of
the MAPKs in Plcb3/ cells, which could account for the
observed inhibition of cytokine production and chemotaxis (Fig-
ure 3). On the other hand, phosphorylation of Akt, another serineImmunity 34, 893–9and threonine kinase involved in Fc3RI-
induced cytokine production (Kitaura
et al., 2000), was only slightly affected by
PLC-b3 deficiency. The transcription
factor NF-kB is involved in production of
various cytokines including IL-6 and
TNF-a and regulated by its inhibitor IkBa
(Hayden and Ghosh, 2004). However,
IkBa degradation was comparable
between WT and Plcb3/ cells (Fig-
ure S2). Therefore, the activities ofMAPKs
are positively regulated by PLC-b3 in an
NF-kB-independent manner.
Fc3RI Stimulation Enhances the
Interactions among PLC-b3, SHP-1,
and Lyn
Next we investigated how PLC-b3 inhibits
Lyn-Tyr396 phosphorylation. Previous
studies show that Lyn kinase activity is
enhanced inB cells frommotheaten viable
(mev/mev) mice that have a loss-of-func-
tion mutation in SHP-1 (Somani et al.,
2001; Yang et al., 1998). We have recently
shown that PLC-b3 binds to SHP-1 andenhances its phosphatase activity (Xiao et al., 2009); PLC-b3
also binds to and promotes Lyn to phosphorylate SHP-1 at
Tyr536and Tyr564,whose phosphorylation is critical for substrate
recognition and enzymatic activation, respectively, in mast cells
and hematopoietic stem and progenitor cells (Xiao et al., 2010).
Interactions between PLC-b3, SHP-1, and Lyn are increased by
growth factor stimulation in these cells. Thus, PLC-b3 in the SPS
complex appears to provide a platform on which efficient
enzyme-substrate interactions (i.e., SHP-1-Stat5 [signal trans-
ducer andactivatorof transcription5]andLyn-SHP-1 interactions)
take place (Xiao et al., 2009, 2010). These and other (Hibbs et al.,
2002; Xiao et al., 2005) observations suggest that SHP-1 might
dephosphorylate Lyn-Tyr396. Consistent with this notion, Lyn,
but not other SFKmembers, contains an evolutionarily conserved
kinase tyrosine-based inhibitory motif, KTIM (Abu-Dayyeh et al.,
2010), to which SHP-1 can bind to recognize its substrate
(Abu-Dayyeh et al., 2008). The direct interaction between SHP-1
and Lyn was confirmed by pull-down assays with glutathione
S-transferase (GST)-SHP-1 and recombinant Lyn (Figure S3), as
described previously (Yoshida et al., 1999).04, June 24, 2011 ª2011 Elsevier Inc. 897
Figure 4. Lyn Activity and Tyrosine Phosphorylation of Lyn Targets Are Upregulated in Plcb3–/– Mast Cells
(A and B) BMMCs were sensitized overnight with IgE and stimulated with 100 ng/ml DNP23-HSA for the indicated periods. Cell lysates were analyzed by SDS-
PAGE followed by immunoblotting with the indicated antibodies.
(C) Immunoprecipitates of Fc3RI b chain and of Syk were analyzed by immunoblotting with phosphotyrosine mAb, followed by reprobing of the blots with anti-
Fc3RI b and anti-Syk, respectively.
(D) Analysis of SHIP-1 phosphorylation was performed as described in (A) and (C). Immunoblotting results are representative of two independent experiments.
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other components of the SPS complex are affected by Fc3RI
stimulation. Because PLC-b3 expression was low in WT
BMMCs, we overexpressed PLC-b3 C-terminal (CT) domain
(PLC-b3-CT), which is mapped as the SHP-1-binding site (Xiao
et al., 2009). We found that Lyn was coimmunoprecipitated
with SHP-1 and that the Lyn-SHP-1 interaction was enhanced
by IgE+Ag stimulation (Figure 6A, lanes 1–4). This interaction
was reduced in Plcb3/ mast cells but enhanced in PLC-b3-
CT-expressing Plcb3/ cells (Figure 6A, lanes 3 and 4 versus
lanes 5 and 6), indicating that PLC-b3 enhances the interaction
between Lyn and SHP-1. Coimmunoprecipitations between
Lyn and PLC-b3-CT (Figure 6A, lanes 3 and 4 versus lanes 5
and 6) and between SHP-1 and PLC-b3-CT (Figure 6A, lane 1
versus lane 2) were also increased by IgE+Ag stimulation. In
addition to its direct interaction with SHP-1 (Xiao et al., 2009),
PLC-b3-CT was shown to directly interact with Lyn in pull-
down assays (Figure S3). These results show that interactions
among Lyn, SHP-1, and PLC-b3 are enhanced by Fc3RI stimula-
tion. They also support the notion that the physical proximity
between Lyn and SHP-1 caused by their interactions with
PLC-b3-CT allows SHP-1 to dephosphorylate Lyn-Tyr396 and
to repress Lyn activity.
We next examinedwhether PLC-b3-CT can revert the reduced
cytokine production in Plcb3/ cells. Retroviral transduction
with PLC-b3-CT increased the production of IL-6 and TNF-a898 Immunity 34, 893–904, June 24, 2011 ª2011 Elsevier Inc.upon Fc3RI stimulation, albeit to a lesser extent than those
with WT cells (Figure 6B and data not shown). Cytokine produc-
tion in Plcb3/ cells expressing WT PLC-b3 or the catalytically
inactive mutant E362G was similar to that in WT cells expressing
empty vector. The results suggest that cytokine production is
independent of the catalytic function of PLC-b3 but dependent
on its adaptor function via the CT domain. The smaller effect of
PLC-b3-CT compared to full-length PLC-b3 seems to be due
to the lack of subcellular localization signals in PLC-b3-CT.
Expression of PLC-b3-CT in Plcb3/ cells reduced Lyn-
Tyr396 and SHIP-1-Tyr1020 phosphorylation (Figure 6C),
suggesting the importance of the PLC-b3-SHP-1-Lyn axis in
regulation of cytokine production.
Physical Relationship of PLC-b3 with Fc3RI
and Downstream Signaling Molecules
PLC-b3 can directly interact with Lyn (Figure S3) and SHP-1
(Xiao et al., 2009), proteins previously shown to physically
interact with Fc3RI (Jouvin et al., 1994; Kimura et al., 1997b;
Xiao et al., 2005). We next tested whether PLC-b3 can interact
with Fc3RI. As shown in Figure 6D, Fc3RI b was constitutively
coimmunoprecipitated with PLC-b3. Furthermore, three regions
of PLC-b3, i.e., the N-terminal pleckstrin homology-EF hand
domains, the C-terminal half of the catalytic domain Y and C2
domain, but not the CT domain, could bring down Fc3RI b and
g chains in mast cell lysates (Figure S4), corroborating Fc3RI’s
Figure 5. Phosphorylation of MAPKs Is Largely Decreased in Plcb3–/– Mast Cells
BMMCs were sensitized overnight with IgE and stimulated with 100 ng/ml DNP23-HSA for the indicated periods.
(A) Phosphorylation events were analyzed by immunoblotting with antibodies to phospho-LAT (Tyr191), phospho-Btk (Tyr223), and phospho-PLC-g2 (Tyr1217).
Blots were subsequently stripped and reprobed with antibodies to LAT, Btk, and PLC-g2.
(B) Phosphorylation of MAPKs and Akt were similarly analyzed. JNK2 is indicated by bars. The lines between lanes separate different parts of the same gel.
Representative of three independent experiments.
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PLC-b3 resides in nonlipid raft fractions (data not shown),
whereas substantial proportions of Fc3RI and Lyn (Field et al.,
1995) and the majority of LAT molecules (Wilson et al., 2004)
were present in lipid rafts.
Interestingly, tyrosinephosphorylationamountsofLAT,SHIP-1,
and other downstream signaling molecules were not high in
unstimulated Plcb3/ mast cells, unlike Lyn, Fc3RI b, and Syk
(Figures 4 and 5). Pull-down experiments showed that no parts
of PLC-b3 bound to LAT or SHIP-1 in lysates of mast cells (Fig-
ure S4). Thus, it is unlikely that PLC-b3 can interact with these
molecules constitutively. This was corroborated by the absence
of coimmunoprecipitation of PLC-b3 with LAT or SHIP-1 (Fig-
ure 6D). Fc3RI b chain did not coimmunoprecipitate with either
LAT or SHIP-1 under the conditions used (Figure 6D). The ability
of PLC-b3 to physically interact with Fc3RI and Lyn without
Fc3RI stimulation may be related to constitutive tyrosine phos-
phorylation of Fc3RI b, Lyn, and Syk in Plcb3/ cells, whereas
the absence of PLC-b3 interactions could explain the absence
of constitutive tyrosine phosphorylation of LAT, SHIP-1, and other
downstream signaling molecules.
mev/mev and Plcb3–/– Mast Cells Exhibit Similar
Fc3RI-Dependent Phenotypes
If SHP-1 suppresses Lyn kinase activity in a PLC-b3-dependent
manner, one would expect similar phenotypes in mev/mev and
Plcb3/ mast cells. Indeed, IgE+Ag-stimulated mev/mev cells
produced significantly lower amounts of IL-6 and TNF-a than
WT cells (Figure 7A and data not shown). Consistent with the
notion that Lyn is a SHP-1 substrate, Lyn-Tyr396 phosphoryla-
tion was increased in resting and IgE+Ag-stimulated mev/mevcells (Figure 7B), whose aberrant SHP-1 proteins have only
10%–20% activity of WT enzyme (Kozlowski et al., 1993). Phos-
phorylation of SHIP-1, another Lyn target, was also enhanced
(Figure 7B). Moreover, phosphorylation of MAPKs was reduced
in mev/mev cells, similar to that in Plcb3/ cells (Figure 7C).
To further investigate the positive regulatory roles of PLC-b3
and SHP-1 in cytokine production, we retrovirally transduced
WT mast cells with PLC-b3-CT and SHP-1. We confirmed that
PLC-b3-CT and SHP-1 were expressed by 3- to 5-fold more
over the respective endogenous proteins in the transduced cells
(data not shown). Consistently, PLC-b3-CT- or SHP-1-overex-
pressing cells produced higher amounts of IL-6 and TNF-a
upon stimulation with IgE+Ag (Figure 7D and data not shown).
Interestingly, this positive effect of SHP-1 is dependent on PLC-
b3, as shown by the fact that SHP-1 overexpression failed to
increase cytokine production in Plcb3/ mast cells (Figure 7D).
On the other hand, the positive effect of PLC-b3-CT is dependent
on SHP-1, as shown by the fact that PLC-b3-CT overexpression
did not increase cytokine production inmev/mev cells (Figure 7D).
These results collectively demonstrated that SHP-1 and PLC-b3
behave similarly for Fc3RI-mediated mast cell activation.
Suppression of SHIP-1 Phosphorylation and Activity
by PLC-b3
Tyrosine phosphorylation of SHIP-1 is Lyn dependent, indicating
that SHIP-1 is the downstream target of Lyn and might be
responsible at least in part for the negative regulatory role of
Lyn in mast cell activation (Hernandez-Hansen et al., 2004;
Phee et al., 2000; Xiao et al., 2005). On the other hand, SHIP-1
tyrosine phosphorylation was increased in Plcb3/ (Figure 4D)
and mev/mev (Figure 7B) mast cells, compared to WT cells.Immunity 34, 893–904, June 24, 2011 ª2011 Elsevier Inc. 899
Figure 6. PLC-b3 Physically Interacts with
Fc3RI, Lyn, and SHP-1 and Regulates Cyto-
kine Production
(A) WT and Plcb3/ BMMCs were retrovirally
transduced with PLC-b3-CT or empty vector and
stimulated with DNP23-HSA for the indicated
periods. Immunoprecipitates (IP) of SHP-1 or Lyn
were analyzed by immunoblotting (IB) with the
indicated antibodies.
(B) WT or Plcb3/ BMMCs transduced with the
indicated retroviral vectors were sensitized over-
night with IgE and stimulated with DNP23-HSA for
16 hr. IL-6 production was measured. Represen-
tative of two independent experiments. *p < 0.05;
**p < 0.01 versus vector control. Error bars
represent SEM.
(C) Plcb3/ BMMCs transduced with PLC-b3-CT
or empty vector were stimulated with DNP23-HSA
for the indicated periods. Immunoblotting was
performed for the indicated proteins. The lot of
anti-pLyn (Y507) antibody used here was different
from that used for Figure 4B and detected p56lyn
preferentially.
(D) BMMCs were stimulated with DNP23-HSA for
the indicated periods. Immunoprecipitates with
anti-PLC-b3 or anti-Fc3RI b were analyzed by
immunoblotting for the indicated proteins. NRG,
normal rabbit IgG; NMG, normal mouse IgG.
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Phospholipase C-b3 in Mast Cell ActivationTyrosine phosphorylation of SHIP-1 is a prerequisite for SHIP-1
localization to the plasma membrane and thus its function
(Edmunds et al., 1999; Phee et al., 2000). Therefore, we ex-
pected to restore SHIP-1 activity in Lyn-deficient cells by using
a rat CD2-SHIP-1 fusion protein that is constitutively located to
the plasma membrane and functions as a constitutively active
form (Freeburn et al., 2002). Indeed, overexpression of CD2-
SHIP-1 in Lyn/ and Lyn/;Plcb3/ cells strongly inhibited
IL-6 and TNF-a production (Figure 7E and data not shown).
Silenced SHIP-1 by lentiviral expression of short-hairpin RNA
increased cytokine production in Plcb3/ mast cells (Figures
S5A and S5B). SHIP-1 can recruit Dok-1 and Dok-2 adaptor
proteins that, upon tyrosine phosphorylation by various PTKs
including Lyn (Liang et al., 2002), bind RasGAP (a potent inhibitor
of Ras) and leads to inhibition of the Ras-ERK pathway (Abram-
son et al., 2003; Mashima et al., 2009). Phosphorylation of Dok-2
at Tyr351was higher inPlcb3/ thanWTmast cells (Figure S5C),
suggesting that the signaling through this pathway contributes to
the reduced ERK activation in Plcb3/ mast cells. Collectively,900 Immunity 34, 893–904, June 24, 2011 ª2011 Elsevier Inc.these results are consistent with the
notion that PLC-b3 and SHP-1 positively
regulatemast cell activation by suppress-
ing Lyn and SHIP-1 activities.
DISCUSSION
PLC-b3 deficiency did not affect Fc3RI-
mediated degranulation. This is consis-
tent with the normal calcium mobilization
and Fyn activity in Plcb3/ BMMCs,
implying that neither the calcium-depen-
dent nor the calcium-independent butrather Fyn-, Gab2-, and RhoA-dependent steps for degranula-
tion (Nishida et al., 2005) are regulated by PLC-b3. Therefore,
we noticed no significant differences in acute-phase PCA
response between WT and Plcb3/ mice. By contrast, we
observed reduced cytokine production in Plcb3/ BMMCs. In
line with this, Plcb3/ mice had less severe late-phase PCA
and airway inflammation. Thus, selective regulation by PLC-b3
of mast cell-mediated late-phase PCA and airway inflammation,
but not acute-phase PCA, is similar to that in mice deficient in B
cell lymphoma 10 (Klemm et al., 2006), mucosa-associated
lymphoid tissue 1 (Klemm et al., 2006), and Zn transporter 5
(Nishida et al., 2009). NF-kB activity that is reduced in the latter
three mice selectively regulates cytokine production. However,
IkBa degradation was not affected in Plcb3/ BMMCs, indi-
cating that a different mechanism(s) is responsible for the un-
coupled regulation of cytokine production versus degranulation
in Plcb3/ mice.
We showed that PLC-b3 regulates many signaling molecules
downstream of Fc3RI. This is striking, because PLC-b3 is a
Figure 7. SHP-1 Inhibits Lyn Activation and
Enhances Cytokine Production in a PLC-
b3-Dependent Manner
(A) IL-6 production by mev/mev BMMCs was
measured as in Figure 3C. n = 4 each.
(B and C) Lysates derived from WT and mev/mev
BMMCs were analyzed by immunoblotting for
phosphorylation of Lyn, SHIP-1, and MAPKs.
JNK2 is indicated by bars.
(D) WT, Plcb3/, and mev/mev BMMCs were
retrovirally transduced with SHP-1 or PLC-b3-CT
and stimulated with DNP23-HSA for 16 hr. IL-6
production was measured. Results are represen-
tative of two independent experiments.
(E) Lyn/ or Lyn/;Plcb3/ BMMCs were ret-
rovirally transduced with rCD2-SHIP1, and IL-6
production was measured after IgE+Ag stimula-
tion. Data are representative of two independent
experiments. Error bars represent SEM.
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Phospholipase C-b3 in Mast Cell Activationtarget downstream of GPCRs and is activated to various extents
by the Ga subunits of the Gq class and bg subunits of the Gai/o
family of G proteins (Rhee, 2001). It should be emphasized that
the function of PLC-b3 in Fc3RI signaling is mediated by its
adaptor but not enzymatic function. Here we found that overex-
pression of the noncatalytic PLC-b3-CT region was sufficient to
increase cytokine production inWT BMMCs. These data and our
previous study showing that PLC-b3-CT can bind SHP-1 (Xiao
et al., 2009) indicate that the regulatory role of PLC-b3 in
Fc3RI-mediatedmast cell activation does not require its catalyticImmunity 34, 893–9activity but its adaptor function that facil-
itates SHP-1 interaction with its
substrates. The phenocopy between
Plcb3/ and mev/mev BMMCs further
supports the notion that SHP-1 and
PLC-b3 function along the same signaling
pathway(s). Interestingly, PLC-b3-CT
domain shares a very low homology
with other PLC-b isoforms. Consistent
with this, other PLC-b members do not
interact with SHP-1, and Fc3RI-mediated
mast cell activation was not affected by
PLC-b2 deficiency (data not shown).
Thus, the role of PLC-b3 in Fc3RI-medi-
ated mast cell activation is unique and
nonredundant among PLC-b isoforms.
The functions of SHP-1 in mast cells
are complex, which might be in part due
to the presence of numerous substrates
of SHP-1. A recent study has identified
a number of protein kinases with KTIM
((I, V, L or S)-x-Y-x-x-(L or V)) that are
potential SHP-1-recognition sites (Abu-
Dayyeh et al., 2010). Interestingly, Lyn is
the only SFK member containing
a KTIM, accounting for the increased
activation-loop tyrosine phosphorylation
of Lyn, but not Fyn, in Plcb3/ and
mev/mev BMMCs. Lyn has been shownto suppress mast cell activation largely via Fc3RI b chain and
SHIP-1 (Furumoto et al., 2004; Hernandez-Hansen et al., 2004;
Xiao et al., 2005). Tyrosine phosphorylation of Fc3RI b chain
was increased only at a resting state in Plcb3/ cells, compared
to WT cells. SHIP-1 phosphorylation was also increased in
Plcb3/ and mev/mev BMMCs over a >10 min period after
Fc3RI stimulation. Constitutive active SHIP-1 suppressed
cytokine production in Lyn/ and Lyn/; Plcb3/ cells and
silencing of SHIP-1 expression enhanced cytokine production
in Plcb3/ cells, placing SHIP-1 downstream of Lyn and04, June 24, 2011 ª2011 Elsevier Inc. 901
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Phospholipase C-b3 in Mast Cell ActivationPLC-b3. Therefore, in our model, PLC-b3 and SHP-1 positively
regulate cytokine production by inhibiting Lyn and SHIP-1
activation; Lyn can interact directly with SHP-1, and the
Lyn-SHP-1 interaction is increased in a PLC-b3-CT-dependent
manner. Thus, it is likely that PLC-b3 docks SHP-1 and Lyn to
facilitate the phosphatase activity of SHP-1 toward Lyn. This is
just like the ability of PLC-b3-CT to augment SHP-1’s activity
to dephosphorylate Stat5 (Xiao et al., 2009). Enhanced Lyn acti-
vation in both Plcb3/ andmev/mev cells could lead to reduced
phosphorylation of MAPKs via the SHIP-1-Dok-RasGAP
(Mashima et al., 2009) and other pathways.
In addition to their positive regulatory functions, we found
negative regulatory activities of PLC-b3 and SHP-1 in the
absence of Lyn (data not shown). Thus, amounts of expression
and catalytic activity of Lyn and SHP-1 may be important in
changing the balance between the positive and negative regula-
tion. Slight changes in the genetic background or cellular
environment might affect the outcomes of Fc3RI stimulation
(Yamashita et al., 2007). We have recently demonstrated that
a slight change in Lyn kinase activity shifts its positive regulatory
role to a negative one (Poderycki et al., 2010). Therefore, a study
on these regulatory pathways might shed insights into the
inconsistent phenotypes reported among motheaten (me/me),
mev/mev, and SHP-1-overexpressing cells. Indeed, Xie et al.
(2000) have shown that overexpression of WT SHP-1 in RBL-
2H3 cells results in increased Fc3RI-dependent cytokine
production without causing changes in degranulation. By
contrast, Nakata et al. (2008) have demonstrated increased
cytokine production and reduced degranulation in me/me
BMMCs. Thus, further analysis is warranted to clarify the roles
of catalytic activity versus adaptor function of SHP-1. Another
interesting issue is how PLC-b3 deficiency differentially affects
basal tyrosine phosphorylation of the proximal signaling mole-
cules (Fc3RI b, Lyn, Syk) versus more distal signaling molecules
(LAT, Btk, PLC-g2, MAPKs, Akt). The ability of Fc3RI b to consti-
tutively coimmunoprecipitate with Lyn (Eiseman and Bolen,
1992) and PLC-b3 but not LAT is consistent with immunoelec-
tron microscopy data showing that resting Fc3RI colocalizes
with Lyn (Wilson et al., 2000) and LAT occurs in small clusters
separate from the receptor (Wilson et al., 2004). Thus, it will be
interesting to study themechanism by which the proximal versus
distal signaling molecules are demarcated. In summary, this
study uncovered unexpected roles of PLC-b3 and SHP-1 in
mast cell activation and provided a new potential therapeutic
target for the treatment of allergic diseases.EXPERIMENTAL PROCEDURES
Cell Culture and Fc3RI Stimulation
Bone marrow cells from WT and mutant mice were cultured in IL-3-containing
medium for 4–6 weeks to generate >95% pure (c-Kit+Fc3RI+) BMMCs. For
stimulation of BMMCs with IgE+Ag, cells were sensitized for 16 hr with
0.5 mg/ml H1 DNP-3-206 IgE and washed twice with Tyrode’s buffer or media
before stimulation with the indicated concentrations of Ag (DNP23-HSA).Retroviral Transduction
pMig or pMX-puro plasmids harboring SHP-1, PLC-b3 and its mutant, or
constitutively active rat CD2-SHIP phosphatase fusion cDNAs were trans-
fected into Plat-E packaging cells to generate recombinant retroviruses.
Bone marrow cells in culture medium containing IL-3 and SCF were infected902 Immunity 34, 893–904, June 24, 2011 ª2011 Elsevier Inc.with retrovirus-containing supernatants; then GFP+ cells were sorted by
FACSAria or puromycin-resistant cells were selected.
Measurement of Histamine, Cytokines, and Migration
Histamine released from BMMCs was measured as previously described
(Kitaura et al., 2003). Cytokines were measured by ELISA. Chemotaxis of
BMMCs was performed in fibronectin-coated Transwell chambers: 1 3 106
cells were loaded into the upper chamber and migration into the lower
chamber containing the indicated concentration of chemoattractant was
measured after 6 hr.
Immunoblotting and Immunoprecipitation
Cells were lysed in 1%NP-40-containing lysis buffer (20 mM Tris-HCl [pH 8.0],
0.15 M NaCl, 1 mM EDTA) containing protease and phosphatase inhibitors.
Lysates or immunoprecipitates were analyzed by SDS-PAGE and transferred
to PVDF membranes. Binding of primary and horseradish peroxidase-conju-
gated secondary antibody and detection with enhanced chemiluminescence
reagents (PerkinElmer) were performed.
PCA
6-week-old mice were sensitized by administration of 500 ng anti-DNP IgE or
PBS (10 ml) to each ear. 24 hr later, mice were challenged intravenously with
100 mg DNP23-HSA in 100 ml PBS or 1% Evans blue dye. Alternatively, 10 ml
of 0.3% dinitrofluorobenzene in acetone and olive oil (4:1) was painted on
both sides of ears. When Evans blue was injected, it was extracted from the
ears 30 min after antigen injection. Ear thickness was periodically measured
when the dye was not injected. The Animal Care and Use Committee of the
La Jolla Institute for Allergy and Immunology approved all mouse experiments.
Airway Inflammation
6-week-old mice were intraperitoneally sensitized with OVA (10 mg/100 ml) at
days 0, 7, 14, 21, 28, and 35. At days 40, 43, and 46, mice were intranasally
challenged with OVA (20 mg/20 ml) or PBS. 24 hr after the last challenge,
mice were sacrificed and bronchoalveolar fluids (BALF) were collected. Lung
tissueswere fixedwith 10% formaldehyde and embedded in paraffin. Sections
were stained with hematoxylin and eosin (H&E) and periodic acid-Schiff (PAS).
Statistical Analysis
Statistical significance was determined with an unpaired two-tailed Student’s t
test. Results are expressed as mean ± SD unless otherwise stated; p < 0.05
was considered significant.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and five figures and can be found with this article online at doi:10.1016/j.
immuni.2011.04.010.
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